Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Mantle Cell Lymphoma

Noel Milpied  1 , Martin Dreyling  2
Nicolaus Kröger  1 , John Gribben  2 , Christian Chabannon  3 , Ibrahim Yakoub-Agha  4 , Hermann Einsele  5
, editors.
In: The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 13.
.
Affiliations
Free Books & Documents
Review

Mantle Cell Lymphoma

Noel Milpied et al.
Free Books & Documents

Excerpt

Mantle cell lymphoma is a distinct lymphoma subtype with a widely varying clinical course. Established high-risk biological factors include blastoid cytomorphology, high cell proliferation (Ki-67 > 67%), and p53 mutations (Aukema et al. 2018). While current first-line approaches are still chemotherapy-based, BTK inhibitors are the preferred targeted approach, especially in early relapse cases (POD24) (Dreyling et al. 2017; Visco et al. 2021). However, cases of relapse/progression under BTK inhibitors display extremely aggressive features with a dismal outcome after conventional regimens (Martin et al. 2016).

PubMed Disclaimer

References

    1. Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131(4):417–20. - PubMed
    1. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv62–71. - PubMed
    1. Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–63. - PubMed
    1. Palomba ML, Gordon LI, Siddiqi T, et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001. ASH; 2020, #118.
    1. Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35(3):787–95. - PubMed

LinkOut - more resources